Interhelical Interaction and Receptor Phosphorylation Regulate the Activation Kinetics of Different Human β1-Adrenoceptor Variants

G protein-coupled receptors represent the largest class of drug targets, but genetic variation within G protein-coupled receptors leads to variable drug responses and, thereby, compromises their therapeutic application. One of the most intensely studied examples is a hyperfunctional variant of the human β 1 -adrenoceptor that carries an arginine at position 389 in helix 8 (Arg-389-ADRB1). However, the mechanism underlying the higher efficacy of the Arg-389 variant remained unclear to date. Despite its hyperfunctionality, we found the Arg-389 variant of ADRB1 to be hyperphosphorylated upon continuous stimulation with norepinephrine compared with the Gly-389 variant. Using ADRB1 sensors to monitor activation kinetics by fluorescence resonance energy transfer, Arg-389-ADRB1 exerted faster activation speed and arrestin recruitment than the Gly-389 variant. Both activation speed and arrestin recruitment depended on phosphorylation of the receptor, as shown by knockdown of G protein-coupled receptor kinases and phosphorylation-deficient ADRB1 mutants. Structural modeling of the human β 1 -adrenoceptor suggested interaction of the side chain of Arg-389 with opposing amino acid residues in helix 1. Site-directed mutagenesis of Lys-85 and Thr-86 in helix 1 revealed that this interaction indeed determined ADRB1 activation kinetics. Taken together, these findings indicate that differences in interhelical interaction regulate the different activation speed and efficacy of ADRB1 variants.The mechanism underlying the hyperfunctionality of the Arg-389 variant of the human β 1 -adrenoceptor is elusive. Results Real-time FRET imaging of the Arg-389 variant in combination with site-directed mutagenesis revealed faster activation kinetics compared with the hypofunctional Gly-389 variant. Conclusion Interhelical interaction of Arg-389 regulates receptor activation speed and efficacy. Significance Our findings deepen the understanding of heterogeneity of drug responses observed for the β 1 -adrenoceptor.